Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Nilo Therapeutics Raises $101M Series A Led by The Column Group, DCVC Bio and Lux Capital
Series AVenture Capital

Nilo Therapeutics Raises $101M Series A Led by The Column Group, DCVC Bio and Lux Capital

•October 9, 2025
•Oct 9, 2025
0

Participants

Nilo Therapeutics

Nilo Therapeutics

company

Alexandria Real Estate Equities

Alexandria Real Estate Equities

investor

The Column Group

The Column Group

investor

DCVC

DCVC

investor

Lux Capital

Lux Capital

investor

Bill & Melinda Gates Foundation

Bill & Melinda Gates Foundation

investor

Deal Summary

Nilo Therapeutics, a NYC-based biotech focused on harnessing neural circuits to restore immune homeostasis, closed a $101M Series A. The round was led by The Column Group, DCVC Bio and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments.

0

Comments

Want to join the conversation?

Loading comments...